



## A 250 µg/week dose of vitamin D was as effective as a 50 µg/d dose in healthy adults, but a regimen of four weekly followed by monthly doses of 1250 µg raised the risk of hypercalciuria

Sara R. Zwart<sup>1</sup>, Howard Parsons<sup>2</sup>, Michael Kimlin<sup>3</sup>, Sheila M. Innis<sup>2</sup>, James P. Locke<sup>4</sup> and Scott M. Smith<sup>4\*</sup>

<sup>1</sup>Division of Space Life Sciences, Universities Space Research Association, Houston, TX, USA

<sup>2</sup>Division of GI/Nutrition, Department of Paediatrics, British Columbia Children's Hospital, Vancouver, BC, Canada

<sup>3</sup>Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia

<sup>4</sup>Human Health and Performance Directorate, National Aeronautics and Space Administration Lyndon B. Johnson Space Center, Mail Code SK3, 2101 NASA Parkway, Houston, TX 77058, USA

(Submitted 13 November 2012 – Final revision received 14 March 2013 – Accepted 15 March 2013 – First published online 18 April 2013)

### Abstract

The risk of vitamin D insufficiency is increased in persons having limited sunlight exposure and dietary vitamin D. Supplementation compliance might be improved with larger doses taken less often, but this may increase the potential for side effects. The objective of the present study was to determine whether a weekly or weekly/monthly regimen of vitamin D supplementation is as effective as daily supplementation without increasing the risk of side effects. Participants were forty-eight healthy adults who were randomly assigned for 3 months to placebo or one of three supplementation regimens: 50 µg/d (2000 IU/d, analysed dose 70 µg/d), 250 µg/week (10 000 IU/week, analysed dose 331 µg/week) or 1250 µg/week (50 000 IU/week, analysed dose 1544 µg/week) for 4 weeks and then 1250 µg/month for 2 months. Daily and weekly doses were equally effective at increasing serum 25-hydroxyvitamin D, which was significantly greater than baseline in all the supplemented groups after 30 d of treatment. Subjects in the 1250 µg treatment group, who had a BMI >26 kg/m<sup>2</sup>, had a steady increase in urinary Ca in the first 3 weeks of supplementation, and, overall, the relative risk of hypercalciuria was higher in the 1250 µg group than in the placebo group ( $P=0.01$ ). Although vitamin D supplementation remains a controversial issue, these data document that supplementing with  $\leq 250$  µg/week ( $\leq 10\,000$  IU/week) can improve or maintain vitamin D status in healthy populations without the risk of hypercalciuria, but 24 h urinary Ca excretion should be evaluated in healthy persons receiving vitamin D<sub>3</sub> supplementation in weekly single doses of 1250 µg (50 000 IU).

**Key words:** Vitamin D: Dietary supplements: Hypercalciuria: Sunlight

The debate over the dietary requirement for vitamin D continues, despite the Institute of Medicine's re-evaluation of dietary requirements, released in 2011<sup>(1)</sup>, with continuing concern that recommendations fall short of actual vitamin D requirements<sup>(2,3)</sup>. Uncertainty and lack of consensus over biomarkers of sufficient and insufficient vitamin D status, and growing evidence for the role of vitamin D in diseases beyond Ca and bone health, further emphasise the importance of continued research on vitamin D nutrition. For individuals with low serum 25-hydroxyvitamin D (25(OH)D), and certain at-risk populations, such as the elderly or those with dark skin or little sunlight exposure, supplements may be advised<sup>(4)</sup>. Concerns over the risks of hypervitaminosis D also continue, and the Institute of Medicine report concluded that serum

concentrations of 25(OH)D >125 nmol/l come with an increased risk of negative effects<sup>(1,4,5)</sup>. One potential side effect of excess vitamin D intake is the increased risk of hypercalciuria, but despite this fact, only a few studies have examined 24 h Ca excretion.

One of the limitations of strategies to improve nutrient status through the use of vitamin supplements is poor compliance with daily supplementation<sup>(6)</sup>. For this reason, large doses taken less frequently may offer advantages to some people. To assess the efficacy and safety of such an approach, we evaluated the effects of vitamin D supplementation in daily and weekly doses, and a high weekly dose followed by monthly doses, on circulating 25(OH)D and vitamin D metabolites and on Ca and related indices in healthy adults.

**Abbreviations:** 24,25(OH)<sub>2</sub>D, 24,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D.

\* **Corresponding author:** Dr S. M. Smith, fax +1 281 483 2888, email scott.m.smith@nasa.gov

We studied vitamin D<sub>3</sub> supplementation given the general consensus that this is more effective<sup>(7–9)</sup>, despite conflicting literature<sup>(10)</sup>. Although only vitamin D<sub>2</sub> is available by prescription, the Internet has opened the door to a wide availability of many doses and forms. We did achieve the aim of evaluating the efficacy and safety of daily, weekly and weekly/monthly doses of vitamin D<sub>3</sub> in a healthy adult population, and we describe their effectiveness at maintaining serum 25(OH)D status and discuss their likelihood of increasing urinary Ca excretion and producing vitamin D toxicity.

## Subjects and methods

The present study was conducted at the Johnson Space Center in Houston, Texas, from June 2008 to September 2009. The study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Johnson Space Center Committee for the Protection of Human Subjects. Participants were recruited from local advertising at Johnson Space Center. Written informed consent was obtained from all subjects.

After passing a general physical examination, subjects were screened for serum 25(OH)D; blood urea N; serum creatinine, Mg, P and Ca; and 24 h urinary Ca excretion. Subjects who had urinary Ca >7.5 mmol/d or a BMI >30 kg/m<sup>2</sup>, who took >40 µg/d (>400 IU/d) of supplemental vitamin D or who smoked were excluded from participation. After screening, forty-eight subjects (*n* 31 men and *n* 17 women) met the eligibility criteria and were randomly assigned to one of four dosage groups: placebo, or vitamin D<sub>3</sub> as 50 µg/d (2000 IU/d), 250 µg (10 000 IU) once per week or 1250 µg (50 000 IU) once per week for 4 weeks and then once per month for 2 months for a total of 3 months. For reporting purposes in the tables, this group will be referred to as the group receiving 1250 µg/month. The placebo group was randomised to placebo daily, once per week and once per week for 4 weeks and then once per month for 2 months (*n* 4 per group), to match the vitamin D supplement groups to make sure subjects could not know their treatment group simply by knowing their dosing regimen. Subjects with an initial serum 25(OH)D concentration >85 nmol/l were assigned to the placebo group (*n* 5). Given that these five subjects were not randomly assigned in the present study, this is a study design limitation.

Vitamin D<sub>3</sub> capsules in the amounts of 50, 250, 1250 µg or the placebo (identical in appearance and excipient to the vitamin D capsules) were from Tishcon. The analysis of vitamin D content of the supplements by Covance showed the actual contents of 70.1 (SD 2.0), 330.5 (SD 8.7) and 1544 (SD 30) µg for the 50, 250 and 1250 µg supplements, respectively. The 50 and 250 µg vitamin D and placebo capsules were packaged in blister-sealed pouches to enable compliance tracking. The 1250 µg capsules were taken under supervision.

On study day 1, the subjects arrived after fasting for 8 h. Venous blood was drawn and then subjects were given their first placebo or vitamin D supplement. The subjects were then instructed to collect all urine voided for the next 24 h into the containers provided and to return the samples,

packed in a bag with ice packs provided, on the following day. Collection of fasting blood and a 24 h urine sample (starting immediately after a morning vitamin D dose) was repeated after 30, 60 and 90 d of supplementation. Additional weekly blood and 24 h urine samples were collected from some subjects during the first 21 d of the study, but results were not used in the statistical analyses.

Subjects were trained to complete a 7 d food questionnaire focusing on food sources of vitamin D, modified from a previously described questionnaire<sup>(6,11)</sup>, and they completed this questionnaire for 6 d before and 24 h after each blood collection.

Exposure to UV radiation was measured using polysulfone film dosimeters as described previously<sup>(12)</sup>. Subjects were asked to wear the dosimeters (approximate size 5 × 5 cm) on their shoulder over their clothes for two 24 h periods, the first preceding the first day of sample collection and the second preceding the 2-month blood draw.

After collection, blood was allowed to clot and was centrifuged, and serum was aliquoted into cryotubes. Serum Ca, blood urea N, serum creatinine and the liver enzymes aspartate transaminase and alanine transaminase were measured within 4 d of blood collection. Serum for other analyses was frozen at –70°C and batch-analysed at the end of the study.

Biochemical analytes were measured as described previously<sup>(6,11)</sup>. Our laboratory participated in blinded proficiency testing by the College of American Pathologists for serum Ca, as well as the vitamin D external quality assurance scheme that monitors and reports the accuracy of 25(OH)D and 1,25-dihydroxyvitamin D measurements. Our laboratory also participated in the Accuracy Based Vitamin D Survey by the College of American Pathologists. Liver enzymes, serum creatinine and blood urea N were analysed in a College of American Pathologists-accredited clinical laboratory at the Johnson Space Center.

Levels of 24,25-dihydroxyvitamin D (24,25(OH)<sub>2</sub>D) were measured as described previously<sup>(13)</sup> using Waters MassLynx 4.1 (Waters Corp.), with quantification performed with Waters QuanLynx. For HPLC separation, a solvent gradient of 2 mM-ammonium formate with 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B) at 0.3 ml/min was used, beginning with 95% A/5% B for 2 min, then 40% A/60% B for 2.1 min, then 12% A/88% B for 5 min, and then 2% A/98% B for 3 min. Multiple reaction monitoring consisted of a transition of 574.3 to 298.0 for 24,25(OH)<sub>2</sub>D with a collision energy at 18 V and a cone voltage at 25 V. Ar was used as a collision gas.

## Statistical analyses

Biochemical markers of vitamin D, Ca and bone metabolism were assessed using a two-way repeated-measures ANOVA followed by a *post hoc* Bonferroni *t* test to determine differences from baseline when there was a main effect (time) or a significant interaction term. The  $\alpha$ -level for statistical significance was set at  $P=0.05$ . Multiple linear regression was used to determine the influence of vitamin D intake and UV light exposure on serum 25(OH)D concentration. A two-way repeated-measures ANOVA followed by a Bonferroni *t* test

**Table 1.** Subject demographic data before and throughout the supplementation study (Mean values and standard deviations)

Dose group	Sex (n)		Age (years)		BMI (kg/m <sup>2</sup> )		Body weight (kg)							
							Baseline		30 d		60 d		90 d	
	Male	Female	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
50 µg/d	6	6	36	10	23	2	70	14	70	13	70	14	70	14
250 µg/week	9	3	32	9	25	2	78	13	78	13	78	13	77	13
1250 µg/month*	10	2	35	8	26	3	82	16	81	17	81	16	80	16
Placebo	6	6	37	9	25	3	72	11	71	12	72	11	72	12

\* The 1250 µg/month group took one 1250 µg pill each week for the first 30 d and then one pill per month for the next 2 months. There were no significant changes in body weight over time, nor were there baseline differences between the groups for age or BMI.

were used to determine the effects of weekly 1250 µg supplementation and BMI during the first 30 d of the study. A relative-risk test was performed to compare the relative risk of hypercalciuria in the group taking the 1250 µg dose and the placebo group once supplementation had started. For parathyroid hormone, two data points were lower than the lower limit of detection. For statistical analyses (and mean and standard deviation calculations), we used the lower limit of detection as the value for those data points.

All data reported are means and standard deviations, and all statistical analyses were completed with SigmaPlot 12.0 (Systat Inc.), unless noted otherwise.

## Results

No significant group differences were found in age, BMI, body weight, dietary vitamin D intake or UV exposure (Tables 1 and 2). Compliance, as determined by pill counts and subject questioning, was >96% for all groups. The 1250 µg supplements and respective placebos were taken under supervision.

Serum 25(OH)D (Table 3) increased significantly over time ( $P < 0.001$ ) and was significantly higher after 30 d than at baseline in all the three groups taking vitamin D, but not in

the placebo group. Serum 25(OH)D was best predicted from dietary vitamin D intake assessed at baseline and 60 d ( $P < 0.001$ ); UV exposure in the 24 h before blood collection had no influence on 25(OH)D (data not shown).

Serum 24,25(OH)<sub>2</sub>D (Table 3) was higher at 30, 60 and 90 d of supplementation than at baseline in all of the groups taking vitamin D; at 90 d, it was significantly higher in the groups taking 50 or 1250 µg vitamin D than in those taking 250 µg vitamin D. As a percentage of 25(OH)D, 24,25(OH)<sub>2</sub>D was significantly greater at 30, 60 and 90 d of the study than at baseline ( $P < 0.01$ ).

Vitamin D supplementation had no effect on serum parathyroid hormone (Table 3). However, as expected, serum parathyroid hormone was inversely correlated with 25(OH)D ( $r = 0.22$ ,  $P < 0.001$ ) and 24,25(OH)<sub>2</sub>D ( $r = 0.24$ ,  $P < 0.001$ ).

Vitamin D supplementation had no effect on serum Ca, vitamin D-binding protein, N-telopeptide, Mg, high-sensitivity C-reactive protein, urea, P or creatinine (data not shown). A significant group effect occurred for bone-specific alkaline phosphatase, but the *post hoc* Bonferroni *t* test yielded no significant differences between the groups (Table 3). The liver enzymes alanine transaminase and aspartate transaminase were elevated in the 250 µg/week group after 90 d of supplementation ( $P < 0.001$  and  $P < 0.05$ , respectively; Table 3).

**Table 2.** Daily UV light exposure and dietary vitamin D intake for 6 d before and 1 d after blood draws

(Mean values and standard deviations,  $n$  12 per group)

	Baseline		30 d		60 d		90 d	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Vitamin D intake* (µg)								
50 µg/d	10	10	10	11	9	11	7	11
250 µg/week	6	6	7	7	7	8	8	8
1250 µg/month†	9	9	8	8	8	8	8	10
Placebo	9	8	8	7	7	5	9	11
UV exposure (MED)								
50 µg/d	1.0	1.2	NA	NA	0.9	1.0	NA	NA
250 µg/week	1.0	0.9	NA	NA	0.4	0.4	NA	NA
1250 µg/month	1.5	2.1	NA	NA	1.3	1.0	NA	NA
Placebo	1.1	1.7	NA	NA	1.2	1.1	NA	NA

MED, minimal erythemal dose; NA, not available.

\* This intake did not include the study supplements. A two-way repeated-measures ANOVA was performed on vitamin D intake data that did not include the study supplements, and there were no differences between the groups or over time.

† The 1250 µg/month group took one 1250 µg pill each week for the first 30 d and then one pill per month for the next 2 months.

**Table 3.** Serum vitamin D status and serum concentrations of liver enzymes, parathyroid hormone and bone-specific alkaline phosphatase for subjects assigned to the different doses of vitamin D or placebo for 3 months‡

(Mean values and standard deviations)

	Baseline		30 d		60 d		90 d	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
25(OH)D (nmol/l)*								
50 µg/d	75 <sup>a</sup>	18	92 <sup>b</sup>	21	98 <sup>b</sup>	24	92 <sup>b</sup>	20
250 µg/week	55 <sup>a</sup>	13	72 <sup>b</sup>	12	77 <sup>b</sup>	10	78 <sup>b</sup>	11
1250 µg/month	66 <sup>a</sup>	19	114 <sup>b</sup>	23	98 <sup>c</sup>	19	100 <sup>c</sup>	28
Placebo	78	25	76	25	76	25	72	22
1,25(OH) <sub>2</sub> D (pmol/l)†								
50 µg/d	145 <sup>a</sup>	51	162 <sup>b</sup>	58	158 <sup>b</sup>	60	157 <sup>b</sup>	47
250 µg/week	108 <sup>a</sup>	31	137 <sup>b</sup>	50	150 <sup>b</sup>	61	143 <sup>b</sup>	40
1250 µg/month	106 <sup>a</sup>	49	131 <sup>b</sup>	38	132 <sup>b</sup>	55	135 <sup>b</sup>	54
Placebo	110 <sup>a</sup>	48	134 <sup>b</sup>	72	124 <sup>b</sup>	43	120 <sup>b</sup>	34
24,25(OH) <sub>2</sub> D (nmol/l)*								
50 µg/d	12 <sup>a</sup>	4	16 <sup>b</sup>	5	18 <sup>b</sup>	6	19 <sup>b</sup>	4
250 µg/week	8 <sup>a</sup>	4	11 <sup>b</sup>	4	13 <sup>b,c</sup>	3	14 <sup>c</sup>	3
1250 µg/month	10 <sup>a</sup>	4	21 <sup>b</sup>	5	20 <sup>b</sup>	4	20 <sup>b</sup>	4
Placebo	12	6	13	6	13	6	12	5
24,25(OH) <sub>2</sub> D (% of 25(OH)D)†								
50 µg/d	16 <sup>a</sup>	4	17 <sup>b</sup>	4	18 <sup>b</sup>	3	21 <sup>b</sup>	6
250 µg/week	14 <sup>a</sup>	5	15 <sup>b</sup>	4	17 <sup>b</sup>	4	18 <sup>b</sup>	3
1250 µg/month	15 <sup>a</sup>	4	19 <sup>b</sup>	3	21 <sup>b</sup>	4	21 <sup>b</sup>	6
Placebo	14 <sup>a</sup>	5	16 <sup>b</sup>	5	16 <sup>b</sup>	5	16 <sup>b</sup>	4
ALT (U/l)*								
50 µg/d	16	4	16	4	17	3	19	8
250 µg/week	16 <sup>a</sup>	5	19 <sup>a</sup>	8	20 <sup>a</sup>	9	32 <sup>b</sup>	26
1250 µg/month	23	15	17	6	15	5	18	7
Placebo	19	9	17	7	19	9	17	7
AST (U/l)**								
50 µg/d	19	3	19	5	19	4	21	6
250 µg/week	18 <sup>a</sup>	3	19 <sup>a</sup>	4	19 <sup>a</sup>	4	25 <sup>b</sup>	12
1250 µg/month	19	7	17	3	16	3	18	4
Placebo	19	4	18	4	18	4	18	5
PTH (pg/ml)								
50 µg/d	23	9	21	10	23	11	23	10
250 µg/week	29	13	26	9	29	12	28	18
1250 µg/month	23	4	23	10	22	4	22	8
Placebo	24	10	24	9	23	8	25	9
BSAP (U/l)								
50 µg/d	21	5	22	6	22	7	21	5
250 µg/week	31	11	30	8	30	9	30	10
1250 µg/month	30	9	31	12	29	9	29	9
Placebo	23	10	23	8	23	9	24	10

25(OH)D, 25-hydroxyvitamin D; 1,25(OH)<sub>2</sub>D, 1,25-dihydroxyvitamin D; 24,25(OH)<sub>2</sub>D, 24,25-dihydroxyvitamin D; ALT, alanine transaminase; AST, aspartate transaminase; PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase.

<sup>a,b,c</sup> Mean values within a row with unlike superscript letters were significantly different ( $P < 0.05$ ; *post hoc* Bonferroni *t* test).

There was a significant group × time interaction effect: \*  $P < 0.001$ , \*\*  $P < 0.05$ .


† There was a significant time effect ( $P < 0.01$ ).

‡ Statistical analyses were performed on the monthly data (baseline and 30, 60 and 90 d time points,  $n$  12). The 7, 14 and 21 d data are included in the table, but were not analysed statistically because of the smaller sample sizes ( $n$  8/9 for the 50 µg group,  $n$  5/6 for the 250 µg group,  $n$  12 for the 1250 µg group and  $n$  9 for the placebo group for the weekly time points). The 1250 µg/month group took one 1250 µg pill each week for the first 30 d and then one pill monthly for the next 2 months.

Of the twelve subjects, four who took 250 µg vitamin D had an alanine transaminase concentration  $> 0.83$  µkat (50 U)/l (normal range 0.10–0.67 µkat (6–40 U/l), and three of these four subjects also had elevated serum aspartate transaminase.

Urinary Ca excretion (Fig. 1) was above the upper limit of normal for twelve samples from subjects in the 1250 µg vitamin D group when expressed as nmol/d (but not when normalised to creatinine), three samples from the 250 µg group, two samples from the 50 µg group and four samples from

the placebo group. However, no significant effect of group was found for mean urinary Ca, creatinine, N-telopeptide, P or Mg excretion at any time (data not shown). When the urinary Ca data (nmol/d) from the 1250 µg/month group were analysed by BMI subgroup over the first 30 d of supplementation (the time when the supplementation was weekly in this group), mean urinary Ca increased significantly only in subjects with a higher BMI (26–30 kg/m<sup>2</sup>,  $n$  6), not in subjects with a lower BMI (20–25 kg/m<sup>2</sup>,  $n$  6). When the urinary Ca



**Fig. 1.** Urinary calcium excretion (24 h) of each subject, for each vitamin D dose group: (a) 50 µg/d (2000 IU/d), (b) 250 µg/week (10 000 IU/week), (c) 1250 µg/week (50 000 IU/week) for 4 weeks and then 1250 µg/month for 2 months and (d) placebo. — Connects the mean for each time point;  $\Delta$  represents individual subject data; --- represents the normal range for urinary calcium (2.5–7.5 nmol/d<sup>(23)</sup>). *n* 8/9 for the 50 µg/d group, *n* 5/6 for the 250 µg/week group, *n* 12 for the 1250 µg/month group and *n* 9 for the placebo group for the 7, 14 and 21 d time points. *n* 12 for all groups at baseline and at 28, 60 and 90 d time points.

data normalised to creatinine were analysed, a similar trend was found, but the interaction was not significant ( $P=0.052$ ). The data were analysed using a two-way repeated-measures ANOVA ( $P<0.05$ ), and a *post hoc* Bonferroni *t* test revealed that after 3 weeks of supplementation, urinary Ca excretion was significantly greater in the group with a higher BMI. The relative risk of urinary Ca excretion being  $>7.5$  mmol/d was compared between the 1250 µg and placebo groups, and the likelihood that urinary Ca exceeded 7.5 mmol/d was higher in the 1250 µg group ( $P=0.01$ ).

## Discussion

The dosing regimens of 50 µg/d, 250 µg/week and 1250 µg/month for 4 weeks and then 1250 µg/month for 2 months were all similarly effective in raising circulating 25(OH) vitamin D concentrations. Of the subjects, one-third taking the weekly rather than the daily dose of vitamin D ended the 90 d study with high levels of alanine transaminase, but this effect was not noted in the subjects taking the monthly dose. One pathway by which the body protects itself against vitamin D toxicity is the conversion of 25(OH)D to 24,25(OH)<sub>2</sub>D. Vitamin D supplementation did increase serum 24,25(OH)<sub>2</sub>D concentrations in all of the supplemented groups. The mean 24 h urinary Ca excretion was not significantly different after 30, 60 or 90 d of taking vitamin D or placebo, but the urinary Ca excretion of all subjects was positively correlated with their serum 25(OH)D concentration ( $P<0.001$ ). Further, more subjects in the 1250 µg vitamin D

group than in the other groups had 24 h urinary Ca excretion above the normal range at some time during the study, with 40% (*n* 5/12) of the subjects in this group showing 24 h urinary Ca excretion typically defined as hypercalciuric (i.e.  $>300$  mg/d) by study day 30. Subjects in the placebo group who had elevated urinary Ca (Fig. 1) at baseline had serum 25(OH)D concentrations of 91 and 78 nmol/l. When we examined the group receiving the 1250 µg/month dose in the first 30 d of the study, we noticed that some subjects' urinary Ca increased steadily over the first 3 weeks of supplementation, and others' urinary Ca did not. When the subjects in that dose group were divided into categories of higher or lower BMI (greater or less than 26 kg/m<sup>2</sup>, which was the median BMI), only the subjects with a higher BMI had an elevation in urinary Ca after the third week of 1250 µg vitamin D<sub>3</sub> supplementation. This interesting result will need further study with more subjects to determine whether it is true that subjects with a higher BMI have an increase in urinary Ca with a weekly dose of 1250 µg/month.

The fact that there were no differences in 25(OH)D responses between the dose groups was not surprising because the total doses were very similar. Total daily doses (calculated from the actual analysed content of the supplements) for the three groups averaged to 70.1, 44.1 and 103 µg/d for the 50 µg/d, 250 µg/week and 1250 µg/month groups. In recent studies conducted in Antarctica on vitamin D<sub>3</sub> supplementation (50 µg/d or 250 µg/week), we found that the efficacy of the supplement was influenced by BMI<sup>(11)</sup> in that the greater the BMI, the smaller the change in

serum 25(OH)D. Given the results from that study and the present study, people with a higher BMI may be likely to take larger doses of vitamin D to increase their vitamin D status, and they are also more likely to have an acute increase in urinary Ca.

Increased urinary Ca excretion is a potential adverse effect of high-dose vitamin D supplementation. Transient elevations in 24 h urinary Ca may not have clinical relevance to healthy individuals, but they are relevant to populations at risk for renal stones. It is worth noting that urinary Ca excretion of >250 mg/d (>6.24 mmol/d) is associated with increased renal stone risk (relative to the general population)<sup>(14)</sup>. In light of the greater acute urinary Ca response in subjects with a higher BMI, their potential for increased renal stone risk with a long-term intermittent high-dose vitamin D supplementation seems clear, and this should be studied further. The present study illustrates the importance of collecting urine for 24 h multiple times when evaluating hypercalciuria risk with intermittent vitamin D supplementation. Despite the fact that hypercalciuria is a primary concern in vitamin D treatment, in the vast majority of studies of vitamin D supplementation, urine was not collected at all<sup>(15–18)</sup>, it was collected only once<sup>(19)</sup> or before or after a long period of supplementation<sup>(20,21)</sup>, or it was collected only as spot urine samples<sup>(22)</sup>, perhaps to avoid the inherent difficulties in having subjects collect complete 24 h urine samples. Other studies have shown modest increases in urinary Ca excretion. After 16 weeks of a weekly dose of 8400 IU (210 µg) vitamin D<sub>3</sub>, urinary Ca excretion tended ( $P=0.08$ ) to increase<sup>(20)</sup>, but it is not known whether urinary Ca excretion was elevated within the first 3 weeks of supplementation. In another study, 1250 µg/week ergocalciferol was administered for 8 weeks. After 8 weeks, the mean urinary Ca excretion was not different from baseline, although eleven of the twenty-nine subjects had an increase > 20 mg/d<sup>(21)</sup>.

One of the limitations of the present study is that we did not collect dietary intake information (other than vitamin D). Beyond this, the results of the present study should be considered preliminary because of our relatively small number of subjects; nonetheless, the relationships identified raise concern for some populations and warrant further study.

### Conclusion

Taking fewer supplements in higher doses conferred no advantage with regard to circulating vitamin D. We found no overt signs of chronic vitamin D toxicity during the study. The data that we report here document a relationship between high-dose vitamin D supplementation and urinary Ca excretion in a subset of individuals. For remote populations, such as space travellers, Antarctic winter crews, submariners and others whose access to medical facilities is limited, the convenience of less frequent supplementation does not seem worth any acute increased risk of hypercalciuria. Given the limited direct evidence of a relationship between vitamin D supplementation and renal stone incidence, it seems that further research on appropriate and safe amounts

of supplemental vitamin D for patients at risk for renal stones is warranted.

### Acknowledgements

The authors are indebted to the participants for their time and efforts in completing the study. We also thank the National Aeronautics and Space Administration (NASA) Nutritional Biochemistry Laboratory for their efforts in the implementation and sample processing for the study. We thank Jane Krauhs for editorial assistance. The present study was funded by the NASA Flight Analogs Project of NASA's Human Research Program. All authors had input to the design of the study. S. R. Z. and S. M. S. oversaw the data collection, management and statistical analysis. S. R. Z., M. K. and S. M. I. analysed the data. All authors interpreted the results of the experiments. S. R. Z. and S. M. S. drafted the manuscript. All authors edited and revised the manuscript, and approved the final version of the manuscript. The authors declare that they have no conflicts of interest.

### References

1. Aloia JF (2011) Clinical review: the 2011 report on dietary reference intake for vitamin D: where do we go from here? *J Clin Endocrinol Metab* **96**, 2987–2996.
2. Heaney RP & Holick MF (2011) Why the IOM recommendations for vitamin D are deficient. *J Bone Miner Res* **26**, 455–457.
3. Holick MF, Binkley NC, Bischoff-Ferrari HA, *et al.* (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **96**, 1911–1930.
4. Institute of Medicine (2011) *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: National Academies Press.
5. Ross AC, Manson JE, Abrams SA, *et al.* (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab* **96**, 53–58.
6. Smith SM, Gardner KK, Locke J, *et al.* (2009) Vitamin D supplementation during Antarctic winter. *Am J Clin Nutr* **89**, 1092–1098.
7. Armas LA, Hollis BW & Heaney RP (2004) Vitamin D<sub>2</sub> is much less effective than vitamin D<sub>3</sub> in humans. *J Clin Endocrinol Metab* **89**, 5387–5391.
8. Heaney RP, Recker RR, Grote J, *et al.* (2011) Vitamin D(3) is more potent than vitamin D(2) in humans. *J Clin Endocrinol Metab* **96**, E447–E452.
9. Tripkovic L, Lambert H, Hart K, *et al.* (2012) Comparison of vitamin D<sub>2</sub> and vitamin D<sub>3</sub> supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. *Am J Clin Nutr* **95**, 1357–1364.
10. Holick MF, Biancuzzo RM, Chen TC, *et al.* (2008) Vitamin D<sub>2</sub> is as effective as vitamin D<sub>3</sub> in maintaining circulating concentrations of 25-hydroxyvitamin D. *J Clin Endocrinol Metab* **93**, 677–681.
11. Zwart SR, Mehta SK, Ploutz-Snyder R, *et al.* (2011) Response to vitamin D supplementation during Antarctic winter is related to BMI, and supplementation can mitigate Epstein-Barr virus reactivation. *J Nutr* **141**, 692–697.
12. Hall LM, Kimlin MG, Aronov PA, *et al.* (2010) Vitamin D intake needed to maintain target serum 25-hydroxyvitamin

- D concentrations in participants with low sun exposure and dark skin pigmentation is substantially higher than current recommendations. *J Nutr* **140**, 542–550.
13. Ding S, Schoenmakers I, Jones K, *et al.* (2010) Quantitative determination of vitamin D metabolites in plasma using UHPLC–MS/MS. *Anal Bioanal Chem* **398**, 779–789.
  14. Pak CYC, Skurla C & Harvey J (1985) Graphic display of urinary risk factors for renal stone formation. *J Urol* **134**, 867–870.
  15. Tau C, Ciriani V, Scaiola E, *et al.* (2007) Twice single doses of 100,000 IU of vitamin D in winter is adequate and safe for prevention of vitamin D deficiency in healthy children from Ushuaia, Tierra Del Fuego, Argentina. *J Steroid Biochem Mol Biol* **103**, 651–654.
  16. Przybelski R, Agrawal S, Krueger D, *et al.* (2008) Rapid correction of low vitamin D status in nursing home residents. *Osteoporos Int* **19**, 1621–1628.
  17. Bacon CJ, Gamble GD, Horne AM, *et al.* (2009) High-dose oral vitamin D<sub>3</sub> supplementation in the elderly. *Osteoporos Int* **20**, 1407–1415.
  18. Sanders KM, Stuart AL, Williamson EJ, *et al.* (2011) Annual high-dose vitamin D<sub>3</sub> and mental well-being: randomised controlled trial. *Br J Psychiatry* **198**, 357–364.
  19. Kimball SM, Burton JM, O'Connor PG, *et al.* (2011) Urinary calcium response to high dose vitamin D<sub>3</sub> with calcium supplementation in patients with multiple sclerosis. *Clin Biochem* **44**, 930–932.
  20. Lips P, Binkley N, Pfeifer M, *et al.* (2010) Once-weekly dose of 8400 IU vitamin D<sub>3</sub> compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency. *Am J Clin Nutr* **91**, 985–991.
  21. Leaf DE, Korets R, Taylor EN, *et al.* (2012) Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers. *Clin J Am Soc Nephrol* **7**, 829–834.
  22. Eisner BH, Thavaseelan S, Sheth S, *et al.* (2012) Relationship between serum vitamin D and 24-hour urine calcium in patients with nephrolithiasis. *Urology* **80**, 1007–1010.
  23. Wu A (2006) *Tietz Clinical Guide to Laboratory Tests*, 4th ed. St Louis, MO: Saunders/Elsevier.